Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Beam Therapeutics (BEAM) EPS (Weighted Average and Diluted) (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with $2.53 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 332.11% to $2.53 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.81, a 82.31% increase, with the full-year FY2025 number at -$0.81, up 82.31% from a year prior.
  • EPS (Weighted Average and Diluted) was $2.53 for Q4 2025 at Beam Therapeutics, up from -$1.1 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.53 in Q4 2025 to a low of -$3.35 in Q1 2021.
  • A 5-year average of -$0.86 and a median of -$1.1 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 271.43% in 2022, then soared 453.7% in 2023.
  • Beam Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.91 in 2021, then skyrocketed by 40.66% to -$0.54 in 2022, then skyrocketed by 453.7% to $1.91 in 2023, then tumbled by 157.07% to -$1.09 in 2024, then soared by 332.11% to $2.53 in 2025.
  • Per Business Quant, the three most recent readings for BEAM's EPS (Weighted Average and Diluted) are $2.53 (Q4 2025), -$1.1 (Q3 2025), and -$1.0 (Q2 2025).